ammonium hydroxide and Cough studies

Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.

Research Excerpts

Excerpt	Relevance	Reference
"This study was designed to determine the effect of active sensitization with ovalbumin (Ova) on cough responses to inhaled irritant gases in mice."	7.85	Cough and expiration reflexes elicited by inhaled irritant gases are intensified in ovalbumin-sensitized mice. ( Hong, J; Khosravi, M; Lee, LY; Lin, RL; Zhang, C, 2017)
"The effect of ammonia on the cough response to citric acid and on substance P release from C-fibers involved in this reflex was assessed."	7.70	Inhibiting effect of ammonia on citric acid-induced cough in pigs: a possible involvement of substance P. ( Beerens, D; Gustin, P; Moreaux, B; Nemmar, A, 2000)
"The feeding of ethylenediamine dihydriodide (EDDI) at the dose levels of 50 and 500 mg/animal/day and urea at the dose level of 45 g/animal/day did not affect duration of clinical signs, body weight gain, magnitude or duration of fever, serum concentration of glutamic oxalacetic transaminase, packed cell volume, and differential white blood cell counts in feeder cattle experimentally infected with infectious bovine rhinotracheitis (IBR) virus."	7.65	Clinical infectious bovine rhinotracheitis in cattle fed organic iodine and urea. ( Brown, LN; Buck, WB; Rosiles, R, 1975)
"This study was designed to determine the effect of active sensitization with ovalbumin (Ova) on cough responses to inhaled irritant gases in mice."	3.85	Cough and expiration reflexes elicited by inhaled irritant gases are intensified in ovalbumin-sensitized mice. ( Hong, J; Khosravi, M; Lee, LY; Lin, RL; Zhang, C, 2017)
" Antitussive evaluations were carried out with cough models in mice and guinea pigs induced by ammonia liquor, capsaicin, and citric acid."	3.81	In vivo evaluation of the antitussive, expectorant and bronchodilating effects of extract and fractions from aerial parts of Peganum harmala linn. ( Cheng, X; Gao, Y; Li, S; Liu, W; Ni, J; Qi, S; Wang, C; Wang, G; Wang, J; Wang, Y; Wang, Z; Zheng, T, 2015)
"We measured capsaicin cough reflex sensitivity in 134 healthy subjects and 88 patients with respiratory disease, and assessed the repeatability over 2 weeks in a subgroup of individuals (healthy subjects, 15; chronic cough patients, 15)."	3.73	Cough and glottic-stop reflex sensitivity in health and disease. ( Birring, SS; Hall, AP; Pavord, ID; Prudon, B; Thompson, JP; Vara, DD, 2005)
" Bronchial asthma model induced by histamine-acetylcholine in guinea pigs was used to observe the antiasthmatic effects."	3.73	[Experimental studies on antitussive, expectorant and antiasthmatic effects of extract from Citrus grandis var. tomentosa]. ( Li, PB; Ma, Y; Su, WW; Wang, YG, 2006)
"The method of strong aqua ammoniae induced cough and sulfur dioxide induced cough, the method of tracheal volume and tracheal spiral line, and phenolsulfonphthalein excretion test."	3.72	[Studies on antitussive, antiasthmatic and expectorant action of chenodeoxycholine acid]. ( Guan, H; Li, P; Zhao, H, 2004)
"The effect of ammonia on the cough response to citric acid and on substance P release from C-fibers involved in this reflex was assessed."	3.70	Inhibiting effect of ammonia on citric acid-induced cough in pigs: a possible involvement of substance P. ( Beerens, D; Gustin, P; Moreaux, B; Nemmar, A, 2000)
"The feeding of ethylenediamine dihydriodide (EDDI) at the dose levels of 50 and 500 mg/animal/day and urea at the dose level of 45 g/animal/day did not affect duration of clinical signs, body weight gain, magnitude or duration of fever, serum concentration of glutamic oxalacetic transaminase, packed cell volume, and differential white blood cell counts in feeder cattle experimentally infected with infectious bovine rhinotracheitis (IBR) virus."	3.65	Clinical infectious bovine rhinotracheitis in cattle fed organic iodine and urea. ( Brown, LN; Buck, WB; Rosiles, R, 1975)
"0 g/kg per day and the no observed adverse effect level was over 16 g/kg per day, which suggested that QFDY is relatively safe for oral medication at the present dose on rats."	1.91	Anti-inflammatory, anti-tussive effects and toxicity evaluation of Qingfei Dayuan granules. ( Daihua, S; Guangzhong, W; Huanbo, C; Hui, HU, 2023)
" Safety endpoints included adverse events, hyperammonemic crises (HACs), and growth and development."	1.46	Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years. ( Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017)
"is widely used for the treatment of cough, bronchitis and asthmatic disorders in the Traditional Chinese Medicine."	1.38	Metabolomic profiling of the flower bud and rachis of Tussilago farfara with antitussive and expectorant effects on mice. ( Jia, JP; Li, ZY; Qin, XM; Sun, HF; Xing, J; Xue, SY; Zhang, FS; Zhang, LZ; Zhi, HJ, 2012)
" Dose-response curves were constructed for the inflammatory reactions induced in nasal cavities, the smooth muscle hyperresponsiveness in the trachea, the permeability of alveolo-capillary barrier, the pulmonary vasomotricity, the cough reflex and the systemic effects."	1.30	[Effect of ammonia on the pig respiratory system. Study of the dose-response relation]. ( Gustin, P, 1999)

Research

Studies (30)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 0 Months to <2 Months Participants

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (30.00)	18.7374
1990's	1 (3.33)	18.2507
2000's	6 (20.00)	29.6817
2010's	10 (33.33)	24.3611
2020's	4 (13.33)	2.80

Authors	Studies
Shi, YH	1
Huang, QW	1
Zhu, SM	1
Zhou, YM	1
Zhang, LJ	1
Huang, WK	1
Shao, JJ	1
Zhou, JL	1
Zhang, WT	1
De Troeyer, K	1
De Man, J	1
Vandebroek, E	1
Vanoirbeek, JA	1
Hoet, PH	1
Nemery, B	1
Vanroelen, C	1
Casas, L	1
Ronsmans, S	1
Soltanzadeh, A	1
Adeli, SH	1
Sadeghi Yarandi, M	1
Heidari, H	1
Mahdinia, M	1
Huanbo, C	1
Hui, HU	1
Daihua, S	1
Guangzhong, W	1
Berry, SA	1
Longo, N	1
Diaz, GA	1
McCandless, SE	1
Smith, WE	1
Harding, CO	1
Zori, R	1
Ficicioglu, C	1
Lichter-Konecki, U	1
Robinson, B	1
Vockley, J	1
Kuang, Y	1
Li, B	1
Fan, J	1
Qiao, X	1
Ye, M	1
Lin, AH	1
Athukorala, A	1
Gleich, GJ	1
Lee, LY	2
Liu, W	1
Cheng, X	1
Wang, Y	2
Li, S	1
Zheng, T	1
Gao, Y	1
Wang, G	1
Qi, S	1
Wang, J	1
Ni, J	1
Wang, Z	1
Wang, C	1
Shang, X	1
Wang, D	3
Miao, X	1
Zhang, J	1
Wang, X	2
Zhang, Y	1
Pan, H	1
Wu, QZ	1
Zhao, DX	1
Xiang, J	1
Zhang, M	1
Zhang, CF	1
Xu, XH	1
Zhang, C	1
Lin, RL	1
Hong, J	1
Khosravi, M	1
Zhu, J	2
Wang, S	2
Ou, Y	1
Wei, D	1
Li, X	1
Chen, X	1
Xu, X	1
Nie, L	1
Long, X	1
Li, ZY	1
Zhi, HJ	1
Xue, SY	1
Sun, HF	1
Zhang, FS	1
Jia, JP	1
Xing, J	1
Zhang, LZ	1
Qin, XM	1
ROSIERE, CE	1
WINDER, CV	1
WAX, J	1
ZAMBONI, P	1
SIRO-BRIGIANI, G	1
Van Hirtum, A	1
Berckmans, D	1
Guan, H	1
Li, P	1
Zhao, H	1
Prudon, B	1
Birring, SS	1
Vara, DD	1
Hall, AP	1
Thompson, JP	1
Pavord, ID	1
Carroll, W	1
Lenney, W	1
Wang, T	1
Spanel, P	1
Alcock, A	1
Smith, D	1
Li, PB	1
Ma, Y	1
Wang, YG	1
Su, WW	1
Faye, O	1
Olschwang, D	1
Giono-Barber, H	1
Pousset, JL	1
Gustin, P	2
Moreaux, B	1
Nemmar, A	1
Beerens, D	1
Rosiles, R	1
Buck, WB	1
Brown, LN	1
Matsumoto, S	1
Polácek, H	1
Hanácek, J	1
Ivan, J	1
Gaman, V	1
Tvrdík, E	1
Plank, L	1
Boushey, HA	1
Richardson, PS	1
Widdicombe, JG	1
Dalhamn, T	1
Raud, A	1
Bálint, G	1
Rablóczky, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)[NCT02246218]	Phase 4	27 participants (Actual)	Interventional	2014-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The percentage of participants with successful transition is based on Investigator response to the question, Has transition to 100% RAVICTI been successful with controlled ammonia? For participants < 2 months of age, after a minimum of 24 hours of ammonia monitoring following the first full dose of RAVICTI alone, the participant was effectively transitioned when following conditions were met: no signs and symptoms of hyperammonemia; ammonia level less than 100 μmol/L (without normalization of ammonia, ie, without conversion of values from local laboratories with varying normal ranges to standardized values); and eligible for discharge per Investigator judgment." (NCT02246218)
Timeframe: Up to Day 4

Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 2 Months to <2 Years Participants

Intervention	percentage of participants (Number)
RAVICTI: Age 0 to < 2 Months	100

"The percentage of participants with successful transition is based on Investigator response to the question, Has transition to 100% RAVICTI been successful with controlled ammonia? For participants 2 months of age and older, after a minimum of 24 hours of ammonia monitoring following the first full dose of RAVICTI alone, the participant was effectively transitioned when following conditions were met: no signs and symptoms of hyperammonemia; ammonia level less than 100 μmol/L (without normalization of ammonia, ie, without conversion of values from local laboratories with varying normal ranges to standardized values); and eligible for discharge per Investigator judgment." (NCT02246218)
Timeframe: Up to Day 4

Plasma PAA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

Intervention	percentage of participants (Number)
RAVICTI: Age 2 Months to < 2 Years	100